Impact of Prior Somatostatin Analogue (SSA) Use on Progression-free Survival (PFS) in Patients with Advanced Nonfunctional Neuroendocrine Tumors (NET) of Lung or Gastrointestinal (GI) Origin: A Secondary Analysis from the RADIANT-4 Study

Roberto Buzzoni1; Carlo Carnaghi2; Rodney Pommier3; Nicola Fazio4; Simron Singh5; Maurizio Voi6; Lida Pacaud7; Antonia Ridolfi8; James Yao9; Edward Wolin10; Marianne Pavel11; Jonathan Strosberg1

1Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano; 2IRCCS Istituto Clinico Humanitas, Rozzano; 3Oregon Health and Science University, Portland, Oregon; 4Istituto Europeo di Oncologia, IRCCS, Milano; 5Sunnybrook Health Sciences Centre, Toronto, Ontario; 6Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; 7Novartis Pharma AG, Basel; 8Novartis Pharma S.A.S., Rueil-Malmaison; 9University of Texas/MD Anderson Cancer Center, Houston, Texas; 10Cedars-Sinai Medical Center, Los Angeles, CA; 11Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin; 12Moffitt Cancer Center, Tampa, Florida

Background: In the RADIANT-4 study, EVE reduced the risk of disease progression or death by 52% vs placebo (PBO; P<0.00001) in patients (pts) with advanced, well-differentiated, progressive, nonfunctional NET of lung/GI tract. This subgroup analysis assessed the impact of prior SSA on PFS in the RADIANT-4 study.

Methods: Pts were randomized (2:1) to receive EVE 10 mg/d or PBO. This analysis reports baseline characteristics, PFS, and safety by prior SSA use.

Results: Of 302 pts randomized, 163 (54%) had any prior SSA use (mostly for tumor control; EVE vs PBO: 53% vs 56%). Baseline characteristics were similar in pts with or without prior SSA. Primary tumor sites in prior SSA group: Lung (23%), GI (65%), and NET of unknown primary (12%). Pts received ≥1 type of SSA, which included octreotide LAR (77%), octreotide SC (14%), lanreotide (14%). Median duration of exposure to prior SSA was 15 mo (range, <0.1-103.5). Median PFS (central review; EVE vs PBO) in prior SSA group was 11.1 (95% CI, 9.2-13.3) mo vs 4.5 (3.6-7.9) mo (HR 0.56; 95% CI, 0.37-0.85); in SSA naive pts, 9.5 (8.2-16.7) mo vs 3.7 (2.4-8.1) mo (HR 0.57; 95% CI, 0.36-0.89). The most common drug-related adverse events (AEs) in EVE arm (prior SSA vs SSA naive) included stomatitis (60% vs 50%), diarrhea (34% vs 28%), and peripheral edema (28% vs 23%).

Conclusion: EVE improves PFS in pts with advanced, progressive, nonfunctional NET of lung/GI tract regardless of prior SSA use. AEs were manageable and consistent with the overall population.

Presented at NANETS 2016